MYC and medulloblastoma: Molecular analyses of primary medulloblastoma have also demonstrated WEE1 overexpression alongside amplification of the MYC family of protooncogenes (MYC or MYCN), which characterize high risk disease in patients from SHH, Group 3, and Group 4 sub-groups.